IMS Company Profiles:Novartis

  • ID: 562766
  • April 2014
  • 108 Pages
  • IMS Health
1 of 3

IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including R&D pipelines, analysts forecasts and events predicted to impact the future.

Use IMS Company Profiles to:

- As a first step to any in-depth competitor analysis exercice
- Understand the influence of companies within therapy areas
- Evaluate the future drivers and potential constraints of companies
- Review independent analysts forecasts and commentaries
- Gain a comprehensive picture of a company's strategic direction

Note: Product cover images may vary from those shown
2 of 3

Corporate Structure

Strategy statement

Highlights a company's strengths / weaknesses and its potential for future growth. The strategy analysis gives you an insight into the following:

- M&A
- Regional strategies
- Therapeutic focus
- R&D strategy
- Licensing activities
- Commentary on future prospects, including brokers' overviews
- Interview with a key person (where available), including quotes and opinions
- Forecasting table (top 30 companies only), showing events with major potential impact

Financial Review

Company sales performance as well as analyst's comments and forecasts.

Company Sales Performance:

- Financial review
- Latest results
- Sales by geographical region & leading country
- Sales by country and subsidiary
- Analysis comments

Product Portfolio

Company Profiles reviews up to 40 products per company, whilst annual reports from the top 10 pharmaceutical companies cover up to a maximum of 10 drugs.

The section shows:

- Summary table of products facing patent expiry.
- Breakdown by relevant therapy area, within which, each product is discussed under the following headings: general, licensing, patents, clinical data, lifecycle management, competition and analysts' forecasts/comments.

R&D Pipelines

Comprehensive details of the projects that the company has in its R&D pipeline including:

- Research pipeline summary table.
- Introduction to the R&D activities of the company.
- Breakdown by relevant therapy area, within which, each project is detailed (up to 2 A4 pages), including information on clinical status and analysts' forecasts.
- Quotes from senior personnel gleaned from conferences may also be included in this section when available.

Key figures

- Sales by business segment.
- Sales by geographical region.

Analyst figures

IMS Sales data

- Pharmaceutical sales by geographical region and leading countries.
- Top 5 third level therapeutic classes.
- Leading international products
- Pharmaceutical sales analysis by age

Employee data

Licensing/Co-Marketing Agreements

Displayed in a tabular format to enable you to have “at a glance” review of the licensing activities of the company.

Three sections are available to review licensing activities:

- Marketed products
- R&D pipeline products
- General research collaborations, including combinatorial chemistry, proprietary technologies etc.

Major Events

Summary of the major events that have affected the company. This includes recent and historical events.

Two sections

- Mergers and Acquisitions
- Other major events

Events are organised in chronological order.

Subsidiaries listing

Mini-profile of each subsidiary that the company has worldwide showing address, major contacts and principal products.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.